glp 1 agonist therapy glp-1_analogs [TUSOM New GLP-1 Guidelines for Type

That glucose-dependent mechanism is the key distinction

From there, doses increased in 2-week intervals until reaching the target maintenance dose

The post hoc analysis of patients only from the PIONEER 6 (evaluating oral semaglutide) and SUSTAIN 6 (evaluating sc semaglutide) studies found a 23.8% reduction in MACEs associated with semaglutide treatment (HR 0.76, 95% CI 0.620.92), especially in the prevention of nonfatal stroke (HR 0.65, 95% CI 0.430.97) [62]

Prevention of cardiorenal complications in people with type 2 diabetes and obesity

Navigating the world of GLP-1 medications shouldn't be something you have to do alone